Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder (SILVER)
|ClinicalTrials.gov Identifier: NCT00322595|
Recruitment Status : Completed
First Posted : May 8, 2006
Last Update Posted : December 22, 2008
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD).
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
|Condition or disease||Intervention/treatment||Phase|
|Generalized Anxiety Disorder||Drug: Quetiapine fumarate Drug: Paroxetine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)|
|Study Start Date :||May 2006|
|Study Completion Date :||May 2007|
- To evaluate the efficacy compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD) at Day 57 (= end of treatment).
- To evaluate efficacy by evaluating response rate.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00322595
Show 89 Study Locations
|Study Director:||Seroquel Medical Science Director||AstraZeneca|